Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia

Acinetobacter baumannii is a common pathogen associated with hospital-acquired pneumonia showing increased resistance to carbapenem and colistin antibiotics nowadays. Infections with A. baumannii cause high patient fatalities due to their capability to evade current antimicrobial therapies, emphasizing the urgency of developing viable therapeutics to treat A. baumannii-associated pneumonia.

Citation:
Shein AMS, Hongsing P, Smith OK, ……. Kicic A, Chatsuwan T, et al. Current and novel therapies for management of Acinetobacter baumannii-associated pneumonia. Crit Rev Microbiol. 2024.

Keywords:
Acinetobacter baumannii; Acinetobacter baumannii-associated pneumonia; current antimicrobial therapies; hospital-acquired pneumonia; novel therapies

Abstract:
Acinetobacter baumannii is a common pathogen associated with hospital-acquired pneumonia showing increased resistance to carbapenem and colistin antibiotics nowadays. Infections with A. baumannii cause high patient fatalities due to their capability to evade current antimicrobial therapies, emphasizing the urgency of developing viable therapeutics to treat A. baumannii-associated pneumonia.